Fluzoparib
- Generic Name
- Fluzoparib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
Histone Deacetylase Inhibitors Show Promise in Breast Cancer Clinical Trials
• Clinical trials evaluating histone deacetylase (HDAC) inhibitors in breast cancer (BRCA) are underway across 24 regions, with the United States and China leading the efforts.
• The majority of these trials are in early phases (Phase I and II), with Chidamide being the most investigated HDAC inhibitor in BRCA clinical trials.
• Combination therapies involving HDAC inhibitors with hormone therapy, immunotherapy, and targeted therapy are being explored to improve outcomes in BRCA.
• Further research into the mechanisms of HDAC inhibitors is essential to optimize their integration into BRCA treatment strategies and overcome resistance.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath